MD Anderson Cancer Center: Triplet-Targeted Therapy Improves Survival for Patients With Advanced Colorectal Cancer and BRAF Mutations
October 01, 2019
October 01, 2019
HOUSTON, Texas, Oct. 1 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- Phase III trial may change standard of care for up to 15% of colorectal cancer patients
* * *
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEA . . .
* * *
- Phase III trial may change standard of care for up to 15% of colorectal cancer patients
* * *
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEA . . .